BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24521695)

  • 1. Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.
    Solomon MT; Miranda N; Jorrín E; Chon I; Marinello JJ; Alert J; Lorenzo-Luaces P; Crombet T
    Cancer Biol Ther; 2014 May; 15(5):504-9. PubMed ID: 24521695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.
    Solomón MT; Selva JC; Figueredo J; Vaquer J; Toledo C; Quintanal N; Salva S; Domíngez R; Alert J; Marinello JJ; Catalá M; Griego MG; Martell JA; Luaces PL; Ballesteros J; de-Castro N; Bach F; Crombet T
    BMC Cancer; 2013 Jun; 13():299. PubMed ID: 23782513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience.
    Cabanas R; Saurez G; Rios M; Alert J; Reyes A; Valdes J; Gonzalez MC; Pedrayes JL; Avila M; Herrera R; Infante M; Echevarria E; Moreno M; Luaces PL; Ramos TC
    MAbs; 2013; 5(2):202-7. PubMed ID: 23575267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
    Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
    J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
    Yang QY; Shen D; Sai K; Mu YG; Jiang XB; Zhang XH; Chen ZP
    Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):232-5. PubMed ID: 21575527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study.
    Jeremic B; Shibamoto Y; Grujicic D; Stojanovic M; Milicic B; Nikolic N; Dagovic A; Aleksandrovic J
    J Neurooncol; 2001 Jan; 51(2):133-41. PubMed ID: 11386410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.
    Mizoe JE; Tsujii H; Hasegawa A; Yanagi T; Takagi R; Kamada T; Tsuji H; Takakura K;
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):390-6. PubMed ID: 17459607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
    Limentani SA; Asher A; Heafner M; Kim JW; Fraser R
    J Neurooncol; 2005 May; 72(3):241-4. PubMed ID: 15937647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
    Chang EL; Loeffler JS; Riese NE; Wen PY; Alexander E; Black PM; Coleman CN
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):65-70. PubMed ID: 9422559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
    Levin VA; Prados MR; Wara WM; Davis RL; Gutin PH; Phillips TL; Lamborn K; Wilson CB
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):75-83. PubMed ID: 7721642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
    Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group.
    Finlay JL; Boyett JM; Yates AJ; Wisoff JH; Milstein JM; Geyer JR; Bertolone SJ; McGuire P; Cherlow JM; Tefft M
    J Clin Oncol; 1995 Jan; 13(1):112-23. PubMed ID: 7799011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.
    Reddy BK; Lokesh V; Vidyasagar MS; Shenoy K; Babu KG; Shenoy A; Naveen T; Joseph B; Bonanthaya R; Nanjundappa ; Bapsy PP; Loknatha ; Shetty J; Prasad K; Tanvir Pasha CR
    Oral Oncol; 2014 May; 50(5):498-505. PubMed ID: 24613543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
    Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
    Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged use of nimotuzumab in children with central nervous system tumors: safety and feasibility.
    Cabanas R; Saurez G; Alert J; Reyes A; Valdes J; Gonzalez MC; Pedrayes JL; Valle L; Infante M; Avila M; Herrera R; Hechavarria E; Rios M; Fernández A; Lorenzo Luaces P; Crombet Ramos T
    Cancer Biother Radiopharm; 2014 May; 29(4):173-8. PubMed ID: 24784755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma.
    Casacó A; López G; García I; Rodríguez JA; Fernández R; Figueredo J; Torres L; Perera A; Batista J; Leyva R; Peña Y; Amador Z; González A; Estupiñan B; Coca M; Hernández A; Puig M; Iglesias M; Hernández A; Ramos M; Rodríquez L; Suarez N
    Cancer Biol Ther; 2008 Mar; 7(3):333-9. PubMed ID: 18094616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasting enhances the response of glioma to chemo- and radiotherapy.
    Safdie F; Brandhorst S; Wei M; Wang W; Lee C; Hwang S; Conti PS; Chen TC; Longo VD
    PLoS One; 2012; 7(9):e44603. PubMed ID: 22984531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
    Kebudi R; Cakir FB; Bay SB; Gorgun O; Altınok P; Iribas A; Agaoglu FY; Darendeliler E
    Childs Nerv Syst; 2019 Jan; 35(1):83-89. PubMed ID: 30417211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.